Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cisplatin + Gemcitabine vs Upfront Surgery in Upper Tract Urothelial Carcinoma (Phase II)
KCT0010825Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, gemcitabine in upper tract urothelial carcinoma (UTUC), renal pelvis cancer, ureteral cancer, sponsored by Boryung. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cisplatingemcitabine
03
Conditions
upper tract urothelial carcinoma (UTUC)renal pelvis cancerureteral cancer
Beyond the preview
Go deeper on KCT0010825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010825.